<i>Short Communication:</i>HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D

Church, Jessica D.; Hudelson, Sarah E.; Guay, Laura; Chen, Shu; Hoover, Donald R.; Parkin, Neil; Fiscus, Susan A.; Mmiro, Francis; Musoke, Philippa; Kumwenda, Newton; Jackson, J. Brooks; Taha, Taha E.; Eshleman, Susan H.

doi:10.1089/aid.2006.0272

Cited by 12 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amino acid substitutions associated with PI resistance were reported as natural non-B HIV-1 variants in treatment-naive patients [17,18]. The prevalence of substitutions obtained was similar to those previously described [19]. In a previous study conducted in Abidjan, the authors have detected key drug resistance mutation in recently HIV-1 infected adults [9].…”

Section: Discussionsupporting

confidence: 78%

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire

Guillaume¹,

Yessé²,

Hortense³

et al. 2012

WJA

View full text Add to dashboard Cite

To clarify the distribution of HIV-1 subtypes and drug resistance-related mutations, we collected and analysed serum from pregnant women who are ARV drug-naive in Abidjan. The prevalence of HIV-1 subtypes and mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women was investigated from plasma of 90 young pregnant primigravida. The HIV-1 pol and env genes were amplified by using primers recognizing conserved viral sequences and sequenced by employing BigDye chemistry. Positions 1-99 of the PR and 1-350 of the RT genes were analyzed for mutations based on the international AIDS society USA panel. In 39 strains which both genes were sequenced including CFR02_AG 30 (76.9%), subtype A 3 (7.7%), CFR06_cpx 2 (5.1%), CFR09_cpx 1 (2.6%), and discordant sequences suggesting the presence of a few number of recombinant involving CRF02-AG and subtype A 3 (7.7%). None of the major drug resistance mutations was detected. The frequent minor mutations associated drug resistance observed were M36I (52%/96.3%), L10I/R/V (19%/35.2%) and L63P (7%/12.9%). The M36I mutation was widespread in all subtypes. Our result demonstrated first a significant level of viral heterogeneity and then only the presence of minor resistance associated mutations. Our study emphasizes the need of HIV sentinel survey in Côte d'Ivoire and shows that pregnant women who are candidates for receiving antiretroviral drug therapies do not contain naturally occurring or preexisting drug resistance mutations. So such drug therapies are likely to be highly effective in this setting.

show abstract

Section: Discussionsupporting

confidence: 78%

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire

Guillaume¹,

Yessé²,

Hortense³

et al. 2012

WJA

View full text Add to dashboard Cite

show abstract

“…[37][38][39] Although early reports in the US placed the prevalence of ARV resistance in ARV-naïve patients at 20-23%, 8-10 more recent estimates have been lower, including those in HIVinfected pregnant women. 16 Minor mutations were similarly distributed among ARVexperienced and unexperienced pregnant women.…”

Section: Discussionmentioning

confidence: 99%

Resistance to antiretrovirals in HIV-infected pregnant women

Weinberg

Forster-Harwood

McFarland

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

“…Women in the PEPI-Malawi trial were likely to have been infected with HIV-1 subtype C [13], [14]. In a previous study of pregnant HIV-infected women enrolled at the same study site, all of the infections analyzed were HIV-1 subtype C [22].…”

Section: Methodsmentioning

confidence: 99%

Antibody Maturation and Viral Diversification in HIV-Infected Women

et al. 2013

Self Cite

View full text Add to dashboard Cite

IntroductionThe Post-exposure Prophylaxis in Infants (PEPI)-Malawi trial evaluated infant antiretroviral regimens for prevention of post-natal HIV transmission. A multi-assay algorithm (MAA) that includes the BED capture immunoassay, an avidity assay, CD4 cell count, and viral load was used to identify women who were vs. were not recently infected at the time of enrollment (MAA recent, N = 73; MAA non-recent, N = 2,488); a subset of the women in the MAA non-recent group known to have been HIV infected for at least 2 years before enrollment (known non-recent, N = 54). Antibody maturation and viral diversification were examined in these women.MethodsSamples collected at enrollment (N = 2,561) and 12–24 months later (N = 1,306) were available for serologic analysis using the BED and avidity assays. A subset of those samples was used for analysis of viral diversity, which was performed using a high resolution melting (HRM) diversity assay. Viral diversity analysis was performed using all available samples from women in the MAA recent group (61 enrollment samples, 38 follow-up samples) and the known non-recent group (43 enrollment samples, 22 follow-up samples). Diversity data from PEPI-Malawi were also compared to similar data from 169 adults in the United States (US) with known recent infection (N = 102) and known non-recent infection (N = 67).ResultsIn PEPI-Malawi, results from the BED and avidity assays increased over time in the MAA recent group, but did not change significantly in the MAA non-recent group. At enrollment, HIV diversity was lower in the MAA recent group than in the known non-recent group. HRM diversity assay results from women in PEPI-Malawi were similar to those from adults in the US with known duration of HIV infection.ConclusionsAntibody maturation and HIV diversification patterns in African women provide additional support for use of the MAA to identify populations with recent HIV infection.

show abstract

Short Communication:HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D

Cited by 12 publications

References 15 publications

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire

Resistance to antiretrovirals in HIV-infected pregnant women

Antibody Maturation and Viral Diversification in HIV-Infected Women

Contact Info

Product

Resources

About

Short Communication:HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D

Cited by 12 publications

References 15 publications

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Na&#239;ve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, C&#244;te d'Ivoire

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Na&#239;ve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, C&#244;te d'Ivoire

Resistance to antiretrovirals in HIV-infected pregnant women

Antibody Maturation and Viral Diversification in HIV-Infected Women

Contact Info

Product

Resources

About

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire

Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire